A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Status Terminated

Clinical Trial Summary

The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression for a subset of NSCLC patients receiving nivolumab is a specific area of clinical need.

Clinical Trial Description

Nab-paclitaxel will be added to standard nivolumab therapy in previously treated advanced stage non-small cell lung cancer to help prevent early progression and to improve progression free survival. The primary endpoint will be to determine if the addition of nab-paclitaxel to nivolumab improves progression free survival compared to nivolumab alone. Retrospective studies will be conducted to analyze blood based immune biomarkers, and tumor biomarkers to better understand the effect that nivolumab combined with chemotherapy has on the immune system in NSCLC. Patients with advanced stage non-small cell lung cancer who have progression of cancer after receiving platinum doublet chemotherapy will be randomized to receive nivolumab with or without nab-paclitaxel. Patients on both arms will receive a maximum of one year of therapy with the option to retreat at progression. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non Small Cell Lung Cancer Recurrent
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Non-Small-Cell Lung Cancer Metastatic
Nonsmall Cell Lung Cancer

Clinical Trial Details

NCT number	NCT02967133
Study type	Interventional
Source	Alliance Foundation Trials, LLC.
Contact
Status	Terminated
Phase	Phase 2
Start date	December 2016
Completion date	January 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06147570` - A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT01312337` - Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)	Phase 2
Completed	`NCT05860582` - A Study of [14C]GB491 in Male Healthy Subjects	Phase 1
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Completed	`NCT02562027` - SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer	N/A
Recruiting	`NCT05358249` - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/Phase 2
Active, not recruiting	`NCT02954523` - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations	Phase 1/Phase 2
Terminated	`NCT03998189` - Metabolic and Microbial Profiling of Lung Cancer	N/A
Not yet recruiting	`NCT03258671` - IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer	N/A
Recruiting	`NCT03838588` - The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Active, not recruiting	`NCT04984811` - NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Phase 2
Recruiting	`NCT05688280` - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS	Phase 1/Phase 2
Recruiting	`NCT02951611` - Effects of Acupuncture Stimulation on Systemic Inflammation	N/A
Recruiting	`NCT02974933` - Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT02980536` - cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
Completed	`NCT02972216` - Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy	Phase 4
Recruiting	`NCT02905591` - A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC	Phase 2
Recruiting	`NCT05873439` - Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC	Early Phase 1
Active, not recruiting	`NCT02981108` - A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT02299141` - Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer	Phase 2